0000896264-24-000138.txt : 20240430 0000896264-24-000138.hdr.sgml : 20240430 20240430160814 ACCESSION NUMBER: 0000896264-24-000138 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240430 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 24897209 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 8-K 1 usna-20240430.htm 8-K usna-20240430
FALSE000089626400008962642024-04-302024-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
April 30, 2024
USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Utah
(State or other jurisdiction of incorporation)
001-3502487-0500306
(Commission File No.)(IRS Employer
Identification No.)
3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)
Registrant's telephone number, including area code: (801) 954-7100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareUSNANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02    Results of Operations and Financial Condition.
On April 30, 2024, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the first quarter ended March 30, 2024. The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company’s corporate website, www.usana.com.
The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.
Item 7.01    Regulation FD Disclosure
The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.
Item 9.01    Financial Statements and Exhibits.
(d)Exhibits


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
USANA HEALTH SCIENCES, INC.
By:/s/ G. Douglas Hekking
G. Douglas Hekking, Chief Financial Officer
Date: April 30, 2024

 EX-99.1 2 q12024earningsreleaseex991.htm EX-99.1 Document

usanacorplogoresized.jpg

USANA Health Sciences Reports First Quarter 2024 Results

SALT LAKE CITY, April 30, 2024 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 30, 2024.

Key Financial & Operating Results
•First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency.
•First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023.
•Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00.

Q1 2024 Financial Performance
Consolidated Results
Net Sales
$228 million
•-8% vs. Q1 2023
•-5% constant currency vs. Q1 2023
•+3% sequentially
•+2% constant currency sequentially
•-$7 million YOY FX impact, or -3%
Diluted EPS
$0.86
•-9% vs. Q1 2023
•-1% sequentially
Active Customers
494,000
•+1% vs. Q1 2023
•+2% sequentially

“Our top line results during the first quarter were driven by a successful sales incentive in mainland China, which helped counter the seasonal slowdown that we experience during the Lunar New Year holiday,” said Jim Brown, President and Chief Executive Officer. “This sales incentive helped us generate 15% year-over-year active customer growth in our largest market, as well as year-over-year and sequential quarter sales growth. Notwithstanding our solid


performance in China, our first quarter results in other key markets did not meet internal expectations and we are actively working to accelerate our business in these markets during 2024.

“During the first quarter we focused on actively engaging with our Associate leaders across the world through several live annual kickoff events, meetings, and trainings. Moreover, early in the second quarter, we hosted both our China National Sales Meeting in Xiamen, China and our Asia Pacific Convention in Kuala Lampur, Malaysia. Attendance at both events was robust and our executive team and Associate leaders came away from both events with increased excitement and motivation to grow their businesses during 2024. We will host additional Associate events throughout the year; all intended to drive further engagement with and productivity from our Associate leaders.

“We also completed our first full quarter of operations in India and we remain excited and optimistic about this important market. We continue to work closely with our local leadership team to expand and build our presence throughout the country. Although we expect its contribution to be small in this first year, we have high expectations for steady and long-term growth in India.”

Q1 2024 Regional Results:
Asia Pacific Region
Net Sales
$185 million
•-7% vs. Q1 2023
•-3% constant currency vs. Q1 2023
•+5% sequentially
•81% of consolidated net sales
Active Customers
395,000
•+2% vs. Q1 2023
•+3% sequentially
Asia Pacific Sub-Regions
Greater China
Net Sales
$128 million
•+3% vs. Q1 2023
•+7% constant currency vs. Q1 2023
•+10% sequentially
Active Customers
274,000
•+13% vs. Q1 2023
•+7% sequentially
North Asia


Net Sales
$21 million
•-28% vs. Q1 2023
•-24% constant currency vs. Q1 2023
•-3% sequentially
Active Customers
45,000
•-17% vs. Q1 2023
•-6% sequentially
Southeast Asia Pacific
Net Sales
$36 million
•-22% vs. Q1 2023
•-19% constant currency vs. Q1 2023
•-8% sequentially
Active Customers
76,000
•-16% vs. Q1 2023
•-5% sequentially

Americas and Europe Region
Net Sales
$43 million
•-12% vs. Q1 2023
•-14% constant currency vs. Q1 2023
•-3% sequentially
•19% of consolidated net sales
Active Customers
99,000
•-6% vs. Q1 2023
•-1% sequentially

Balance Sheet and Share Repurchase Activity
The Company generated $18 million in operating cash flow during first quarter and ended the quarter with $328 million in cash and cash equivalents while remaining essentially debt-free. The Company repurchased 194,000 shares for a total of $9 million during the quarter. As of March 30, 2024, the Company had approximately $62 million remaining under the current share repurchase authorization.

Fiscal Year 2024 Outlook
The Company is reiterating its net sales and earnings per share outlook for fiscal year 2024, as follows:
Fiscal Year 2024 Outlook
Range
Consolidated Net Sales$850 - $920 million
Diluted EPS$2.40 - $3.00



“Strength in our mainland China operations carried our first quarter results,” said Doug Hekking, Chief Financial Officer. “This performance helped offset softness in many other markets where we continue to face a challenging operating environment highlighted by ongoing inflationary pressures.”

Mr. Hekking continued, “We remain committed to engaging with Associate leaders throughout each of our markets and plan to offer additional market-specific incentives throughout the year to improve sales and customer activity levels.”

Management Commentary Document and Conference Call
For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, May 1, 2024 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.





About USANA
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com.

Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking


statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.






Investor contact: Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com

Media contact: Amy Haran
Public Relations
(801) 954-7280



USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)

Quarter Ended
March 30,
2024		April 1,
2023
Net sales$227,800 $248,360 
Cost of sales43,069 48,519 
Gross profit184,731 199,841 
Operating expenses:
Associate incentives95,758 106,070 
Selling, general and administrative64,300 66,926 
Total operating expenses160,058 172,996 
Earnings from operations24,673 26,845 
Other income (expense):
Interest income2,676 1,775 
Interest expense(52)(31)
Other, net(186)(88)
Other income (expense), net2,438 1,656 
Earnings before income taxes27,111 28,501 
Income taxes10,574 10,118 
Net earnings$16,537 $18,383 
Earnings per common share
Basic$0.86 $0.95 
Diluted$0.86 $0.95 
Weighted average common shares outstanding
Basic19,17419,283
Diluted19,30219,328



USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)

As of
March 30,
2024		As of
December 30,
2023
ASSETS
Current assets
Cash and cash equivalents$328,336 $330,420 
Inventories60,870 61,454 
Prepaid expenses and other current assets31,864 25,872 
Total current assets421,070 417,746 
Property and equipment, net98,186 99,814 
Goodwill16,902 17,102 
Intangible assets, net29,105 29,919 
Deferred tax assets11,347 13,284 
Other assets*
52,665 54,892 
Total assets$629,275 $632,757 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$8,266 $10,070 
Line of credit - short term1,320 786 
Other current liabilities103,045 107,989 
Total current liabilities112,631 118,845 
Deferred tax liabilities5,113 4,552 
Other long-term liabilities11,543 12,158 
Stockholders' equity499,988 497,202 
Total liabilities and stockholders' equity$629,275 $632,757 


*Other assets include noncurrent inventories of $2,893 and $3,128 as of 30-Mar-24 and 30-Dec-23, respectively. Total inventories were $63,763 and $64,582 as of 30-Mar-24 and 30-Dec-23, respectively.


USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
SALES BY REGION
(in thousands)
(unaudited)



Quarter EndedChange from prior
year		Percent changeCurrency impact on
sales		% change
excluding currency
impact
March 30, 2024April 1, 2023
Asia Pacific
Greater China$127,615 56.0 %$123,820 49.9 %$3,795 3.1 %$(5,396)7.4 %
Southeast Asia Pacific36,065 15.9 %$46,286 18.6 %(10,221)(22.1 %)(1,495)(18.9 %)
North Asia21,421 9.4 %$29,608 11.9 %(8,187)(27.7 %)(987)(24.3 %)
Asia Pacific Total185,101 81.3 %199,714 80.4 %(14,613)(7.3 %)(7,878)(3.4 %)
Americas and Europe42,699 18.7 %48,646 19.6 %(5,947)(12.2 %)635 (13.5 %)
$227,800 100.0 %$248,360 100.0 %$(20,560)(8.3 %)$(7,243)(5.4 %)



USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION
(unaudited)


Active Associates by Region(1)
(unaudited)
As of
March 30, 2024		As of
April 1, 2023
Asia Pacific:
Greater China71,00036.1 %74,00034.1 %
Southeast Asia Pacific51,00025.9 %61,00028.1 %
North Asia30,00015.2 %35,00016.1 %
Asia Pacific Total152,00077.2 %170,00078.3 %
Americas and Europe45,00022.8 %47,00021.7 %
197,000100.0 %217,000100.0 %


Active Preferred Customers by Region(2)
(unaudited)
As of
March 30, 2024		As of
April 1, 2023
Asia Pacific:
Greater China203,00068.3 %168,00061.3 %
Southeast Asia Pacific25,0008.4 %29,00010.6 %
North Asia15,0005.1 %19,0006.9 %
Asia Pacific Total243,00081.8 %216,00078.8 %
Americas and Europe54,00018.2 %58,00021.2 %
297,000100.0 %274,000100.0 %

(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

 EX-99.2 3 q12024managementcommentary.htm EX-99.2 Document

usanacorplogoresizedb.jpg

USANA Health Sciences, Inc.                         April 30, 2024
Q1 2024 Management Commentary

Key Financial & Operating Results
•First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency.
•First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023.
•Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00.

Overview

Our top line results were driven by a successful sales incentive in mainland China, which helped counter the seasonal slowdown that we experience during the Lunar New Year holiday. This sales incentive helped us generate 15% year-over-year increase in active customers in our largest market, as well as sales growth on both a year-over-year and sequential quarter basis during the first quarter. Our first quarter sales results in other key markets, however, did not meet internal expectations. Consumer spending continued to be negatively impacted by broader inflationary pressures, as we again experienced heightened price-sensitivity among consumers. This created a challenging environment for our Associate leaders to sell products and attract new customers. We are actively working to accelerate our business in these markets during 2024. These plans include market-specific incentives planned throughout the year and a product strategy that provides an emphasis on local/regional offerings.

During the first quarter we continued to focus on actively engaging with our Associate leaders across the world through several live annual kickoff events, meetings, and trainings. Moreover, early in the second quarter, we hosted both our China National Sales Meeting in Xiamen, China and our Asia Pacific Convention in Kuala Lampur, Malaysia. Attendance at both events was


robust and outpaced prior year attendance. For example, our China National Sales Meeting was attended by approximately 17,000 participants. Both events served as a platform to celebrate our Associates' success, engage with our Associate leaders from around the world, and to provide additional training to leaders. Our executive team and Associate leaders came away from both events with increased excitement and motivation to grow their businesses during 2024. We will host additional Associate events throughout the year, all of which are intended to drive further engagement with and productivity from our Associate leaders.

We also completed our first full quarter of operations in India during the quarter and are excited and optimistic about this important market for USANA. During the quarter, our local leadership team made progress on introducing the USANA brand throughout the country to help generate customer acquisition. Meanwhile, our sales & marketing, customer service, and product teams remain in close collaboration as we work to introduce additional USANA products into the market that will resonate with the local population. Although we continue to expect modest net sales contribution from India in this first year, we have high expectations for our long-term growth potential in this market.

Finally, we will execute on several key initiatives this year to generate sales and customer growth, including: 1) Continued engagement with Associate leaders to further support expansion of their businesses; 2) Enhanced, market-specific incentive offerings that reward growth; 3) Growing our sales and customer base in India; 4) Product innovation and development, and; 5) Pursuit of additional acquisition opportunities.
2


Q1 2024 Financial Performance
Consolidated Results
Net Sales
$228 million
•-8% vs. Q1 2023
•-5% constant currency vs. Q1 2023
•-$7 million YOY FX impact, or -3%
•+3% sequentially
•+2% constant currency sequentially
Diluted EPS
$0.86
•-9% vs. Q1 2023
•-1% sequentially
Active Customers
494,000
•+1% vs. Q1 2023
•+2% sequentially
Balance Sheet and Share Repurchase Activity
We generated $18 million in operating cash flow during the first quarter and ended the quarter with $328 million in cash and cash equivalents while remaining essentially debt-free.

As of March 30, 2024, inventories were $64 million, a reduction of approximately $1 million (or 1%) from the year end balance in fiscal 2023. Our in-house manufacturing capabilities provide us with better control of inventory levels and help to mitigate supply chain risks while providing a meaningful contribution to delivering the highest quality nutritional products.

We repurchased 194,000 shares for a total investment of $9 million during the quarter. As of March 30, 2024 we had approximately $62 million remaining under the current share repurchase authorization.

Quarterly Income Statement Discussion
Gross margin increased 60 basis points from the prior year to 81.1% of net sales. The increase can be attributed to favorable impact from market mix, modest price increases, and production efficiencies, partially offset by foreign currency exchange rates and the loss of leverage on fixed-period costs due to lower net sales.

Associate Incentives decreased 70 basis points from the prior year to 42.0% of net sales. The decrease largely reflects lower incentive and promotional expenses in the current year quarter.
3


Selling, General and Administrative expenses increased 130 basis points from the prior year to 28.3% as a percentage of net sales. The relative increase is primarily due to a loss of leverage on lower year-over-year net sales. On an absolute basis, SG&A expenses, decreased $2.6 million compared to the first quarter of 2023 due, in part, to lower variable expenses.

The effective tax rate increased to 39.0% from the 35.5% reported in the first quarter of 2023, which is largely attributable to a change in mix of taxable income by market.

Q1 2024 Regional Results:
Asia Pacific Region
Net Sales
$185 million
•-7% vs. Q1 2023
•-3% constant currency vs. Q1 2023
•+5% sequentially
•81% of consolidated net sales
Active Customers
395,000
•+2% vs. Q1 2023
•+3% sequentially
Asia Pacific Sub-Regions
Greater China
Net Sales
$128 million
•+3% vs. Q1 2023
•+7% constant currency vs. Q1 2023
•+10% sequentially
Active Customers
274,000
•+13% vs. Q1 2023
•+7% sequentially
North Asia
Net Sales
$21 million
•-28% vs. Q1 2023
•-24% constant currency vs. Q1 2023
•-3% sequentially
Active Customers
45,000
•-17% vs. Q1 2023
•-6% sequentially
Southeast Asia Pacific
Net Sales
$36 million
•-22% vs. Q1 2023
•-19% constant currency vs. Q1 2023
•-8% sequentially
Active Customers
76,000
•-16% vs. Q1 2023
•-5% sequentially
4

Greater China: Net sales and local currency sales in mainland China increased 5% and 10% year-over-year, respectively. Active Customers in this market increased 15% year-over-year. Sequentially, regional performance was driven by our mainland China market, where net sales grew 11% (minimal FX impact) and Active Customers increased 8%. The primary driver of year-over-year and sequential performance is attributable to a successful incentive offering during the quarter.
North Asia: Net sales and local currency sales in South Korea declined 27% and 24% year-over-year, respectively, and Active Customers declined 17%. On a sequential basis, net sales and local currency sales declined 3% and 2%, respectively, while Active Customers declined 9%. Both year-over-year and sequential quarter declines reflect ongoing challenges in the local economy, which are negatively impacting consumer spending and making it difficult to attract new customers. Additionally, last year's first quarter included increased purchasing ahead of price increases that did not recur this year.
Southeast Asia Pacific: Net sales in the Philippines declined 27% (minimal FX impact) year-over-year, while Active Customers were 28% lower. Sequentially, both net sales and local currency sales in the Philippines were flat, while Active Customers declined 5%. In Malaysia, net sales and local currency sales declined 25% and 20% year-over-year, respectively, while Active Customers declined 17% year-over-year. Sequentially, net sales and Active Customers in Malaysia decreased 7% and 17%, respectively. Year-over-year results in these two markets reflect increased purchasing ahead of price increases in the prior-year quarter, which did not recur this year, along with continued price-sensitivity among consumers due to inflationary pressures.
Americas and Europe Region
Net Sales
$43 million
•-12% vs. Q1 2023
•-14% constant currency vs.Q1 2023
•-3% sequentially
•19% of consolidated net sales
Active Customers
99,000
•-6% vs. Q1 2023
•-1% sequentially
5


Americas and Europe Region: Both net sales and local currency sales in Canada decreased 19% from the prior year, while Active Customers declined 9%. Net sales in the United States declined 16% and Active Customers decreased 5% on a year-over-year basis. Sequentially, net sales in Canada declined 5% (minimal FX impact) while Active Customers were flat. In the United States, net sales declined 6% sequentially while Active Customers were flat. We continue to experience a price-sensitive consumer in these two markets, which made it challenging to generate sales momentum and customer growth in the quarter. This factor, along with increased purchasing ahead of price increases in the prior-year quarter which did not recur this year, are reflected in year-over-year results.

Fiscal Year 2024 Outlook
The Company is reiterating its net sales and earnings per share outlook for fiscal year 2024, as follows:
Fiscal Year 2024 Outlook
Range
Consolidated Net Sales$850 - $920 million
Diluted EPS$2.40 - $3.00

Our outlook for the year reflects:
•An operating margin in the range of 8% to 9%
•An annual effective tax rate of approximately 38% to 40%
•An annualized diluted share count of 19.3 million
•An unfavorable modest currency exchange rate impact on net sales
Notably, the cadence and magnitude of promotional activity is expected to be lower during the second quarter, particularly in mainland China. As a result of the typical slowdown in activity following a strong promotional period, we anticipate lower sequential results in the second quarter. Nonetheless, we remain confident and actively engaged with our Associate leaders to drive sales and customer growth.

6

Our balance sheet is healthy and we expect to continue generating solid cash flow that will allow continued investment in strategies to create long-term value for our stakeholders. We remain committed to our strategies and are confident in the long-term prospects for our business.

Jim Brown
President and CEO

Douglas Hekking
CFO

7


Safe Harbor
This Management Commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this Management Commentary should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this Management Commentary set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

8

Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

Investor contact:Andrew Masuda
Investor Relations
(801) 954-7210

investor.relations@usanainc.com
Media contact:Amy Haran
Public Relations
801-954-7280

9
 EX-101.SCH 4 usna-20240430.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 usna-20240430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 usna-20240430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 usanacorplogoresized.jpg begin 644 usanacorplogoresized.jpg MB5!.1PT*&@H -24A$4@ !/( &E" 8 !P3=C= 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end GRAPHIC 8 usanacorplogoresizedb.jpg begin 644 usanacorplogoresizedb.jpg MB5!.1PT*&@H -24A$4@ !/( &E" 8 !P3=C= 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 30, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 30, 2024
Entity Registrant Name USANA HEALTH SCIENCES, INC.
Entity Incorporation, State or Country Code UT
Entity File Number 001-35024
Entity Tax Identification Number 87-0500306
Entity Address, Address Line One 3838 West Parkway Boulevard
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84120
City Area Code 801
Local Phone Number 954-7100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol USNA
Security Exchange Name NYSE
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000896264

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.usana.com/role/Cover Cover Cover 1 false false All Reports Book All Reports usna-20240430.htm usna-20240430.xsd usna-20240430_lab.xml usna-20240430_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "usna-20240430.htm": { "nsprefix": "usna", "nsuri": "http://www.usana.com/20240430", "dts": { "inline": { "local": [ "usna-20240430.htm" ] }, "schema": { "local": [ "usna-20240430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "usna-20240430_lab.xml" ] }, "presentationLink": { "local": [ "usna-20240430_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.usana.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "usna-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "usna-20240430.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0000896264-24-000138-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000896264-24-000138-xbrl.zip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usna-20240430_htm.xml IDEA: XBRL DOCUMENT 0000896264 2024-04-30 2024-04-30 false 0000896264 8-K 2024-04-30 USANA HEALTH SCIENCES, INC. UT 001-35024 87-0500306 3838 West Parkway Boulevard Salt Lake City UT 84120 801 954-7100 false false false false Common Stock, $0.001 par value per share USNA NYSE false